In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Low PCSK9 plasma level is an independent predictor of coronary atherosclerotic burden in patients with stable coronary artery disease

Session Poster Session 7

Speaker Chiara Caselli

Congress : ESC Congress 2019

  • Topic : imaging
  • Sub-topic : Computed Tomography: Plaque Imaging
  • Session type : Poster Session
  • FP Number : P6168

Authors : C Caselli (Pisa,IT), R Ragusa (Pisa,IT), S Del Turco (Pisa,IT), M De Graaf (Leiden,NL), G Basta (Pisa,IT), A Scholte (Leiden,NL), R De Caterina (Pisa,IT), D Neglia (Pisa,IT)

C Caselli1 , R Ragusa1 , S Del Turco1 , M De Graaf2 , G Basta1 , A Scholte2 , R De Caterina3 , D Neglia4 , 1Institute of Clinical Physiology (IFC) - Pisa - Italy , 2Leiden University Medical Centre - Leiden - Netherlands (The) , 3University Hospital of Pisa - Pisa - Italy , 4Fondazione Toscana Gabriele Monasterio - Pisa - Italy ,

On behalf: EVINCI study


Background. Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of LDL cholesterol levels and has emerged as a new therapeutic target in coronary artery disease (CAD). Plasma PCSK9 levels have also been related to other components of the lipid profile associated with atherosclerotic risk.

Purpose. Aim of the present study was to evaluate the relationship of plasma PCSK9 levels with lipid profile and measures of coronary atherosclerotic burden and risk in patients with stable CAD enrolled in the European EValuation of INtegrated Cardiac Imaging (EVINCI) study.

Methods. PCSK9 was measured in 412 patients (60.3±8.6 years, 256 males) with symptoms of stable CAD fully characterized by clinical risk factors, bio-humoral profiles, and treatment. All patients underwent coronary computed tomography (CT) angiography to assess the presence and characteristics of coronary atherosclerosis. We calculated an individual CT risk score, expressing the coronary atherosclerotic burden, combining extent, severity, composition, and location of plaques.

Results. Patients were divided in groups according to PCSK9 quartiles: I (<136 ng/mL), II-III (136-266 ng/mL), and IV quartile (>266 ng/mL). LDL and HDL-cholesterol levels were significantly lower while total/HDL-cholesterol ratio was significantly higher in patients in the quartile I than in those in quartile IV (Figure A). CT angiography documented normal vessels in 30 and obstructive CAD in 35% of cases. Compared with patients with the highest levels (quartile IV), patients with the lowest PCSK9 levels (quartile I) had a higher CT risk score, a higher number of mixed plaque and higher hs-cTnI plasma levels (Figure B). PCSK9 itself was not associated with obstructive CAD. At multivariable analysis including clinical variables, medications and lipid variables PCSK9 was an independent predictor of the CT risk score (Coefficient - 0.129 (SE 0.03), p <0.0001), together with age, male gender and statin treatment.

Conclusion. PCSK9 levels are independently and inversely associated with the coronary atherosclerotic burden in patients with stable CAD.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are